Federal Trade Commission
600 Pennsylvania Avenue, N.W.
Washington
D.C.
20580
United States
Tel: 877-382-4357-Or-202-326-2222
Website: http://www.ftc.gov/
80 articles about Federal Trade Commission
-
The Federal Trade Commission is challenging over 100 pharmaceutical patents held by prominent drugmakers, including AbbVie, AstraZeneca and Boehringer Ingelheim, for their listings.
-
Week in Review: Amgen-Horizon Deal Moves Forward, First 10 Drugs for IRA Price Negotiation, Layof...
9/1/2023
$27.8B Amgen-Horizon deal gets FTC clearance with restrictions; the White House names first 10 drugs subject to Medicare price negotiations; Sage Therapeutics axes 40% of staff. -
The Federal Trade Commission released new draft guidelines for assessing mergers, while an Alzheimer’s conference yielded promising data and J&J kicked off Q2 earnings season with a sound beat.
-
The proposed regulatory framework provides a tougher stance on mergers, impacting industries such as biopharma where the FTC's recent lawsuit seeks to block Amgen’s Horizon Therapeutics buy.
-
The companies have filed their own suit against the Federal Trade Commission, claiming the FTC’s attempt to legally block their $28 billion merger is unconstitutional.
-
Horizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by Amgen
5/16/2023
Horizon Therapeutics plc issued the following statement in response to the FTC’s complaint seeking to block Amgen’s proposed acquisition of the Company.
-
Amgen Responds to FTC Action Re: Proposed Acquisition of Horizon Therapeutics
5/16/2023
Amgen issued the following statement in response to the U.S. Federal Trade Commission's complaint seeking to block the company's proposed acquisition of Horizon Therapeutics plc:.
-
The vote came just over one week after the FTC announced it would probe claims regarding the role the middlemen play in determining retail prices of prescription drugs.
-
Calls for a reform of drug prices have become a regular occurrence, particularly in the midst of political campaigns. Yet a new report shows the median price of a new drug launched in 2021 was $180,000.
-
AbbVie’s Allergan Aesthetics announced it was buying Soliton in a deal worth about $550 million. Now, the Federal Trade Commission has requested additional information about the deal.
-
Grail presents its first data from the interventional PATHFINDER trial of Galleri, its multi-cancer early detection blood test. Galleri is now available in the U.S. by prescription.
-
The goal is to “identify concrete and actionable steps to review and update the analysis of pharmaceutical mergers.”
-
The U.S. Federal Trade Commission gave the green light to the $63 billion merger of AbbVie and Allergan. That leaves one last hurdle for the two companies, approval from the Irish High Court.
-
FDA and FTC Issue Warning Letters to Seven Companies Selling Fraudulent COVID-19 ‘Treatments’
3/10/2020
The U.S. Food and Drug Administration is putting a halt to the sale of alleged treatments for COVID-19 due to concerns about the safety risks these products could have to the public. -
Vizient to Present at FDA/FTC Workshop on a Competitive Marketplace for Biosimilars
3/9/2020
Vizient, Inc. announces it will participate in Food and Drug Administration /Federal Trade Commission Workshop on a Competitive Marketplace for Biosimilars in Silver Spring, Maryland.
-
FDA and FTC Announce New Efforts to Further Deter Anti-Competitive Business Practices, Support Competitive Market for Biological Products to Help Americans
2/3/2020
The U.S. Food and Drug Administration and the Federal Trade Commission today signed a joint statement regarding enhanced collaboration in support of a robust marketplace for biological products, including the critical adoption of biosimilars and interchangeable products.
-
The FTC alleges that Illumina is trying to unlawfully maintain a monopoly in the U.S. market for next-generation DNA sequencing systems by removing PacBio as a competitive threat.
-
On Thursday, FTC staff reviewing Roche’s $4.8 billion bid for Spark gave the deal a thumbs up after reviewing the potential merger.
-
Specifically, the civil subpoenas were issued to determine if the company had violated antitrust laws with its rheumatoid arthritis drug Remicade.
-
“Bristol-Myers Squibb is committed to working with regulatory authorities around the world on the proposed combination with Celgene,” the company stated. “The company is focused on realizing the promise of the transaction, and is continuing to work to complete the transaction on a timely basis.”